Biotech · Private company · Yonkers, NY, US
CONTRAFECT Corp
SEC CIK 0001478069
Track this companyFree. Adds CONTRAFECT Corp to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- ExebacasePhase 3 · Staphylococcus Aureus BacteremiaClinicalTrials.gov · fetched Nov 12, 2026
- CF-301Phase 2 · Staphylococcus Aureus BacteremiaClinicalTrials.gov · fetched Nov 12, 2026
- CF-301Phase 1 · Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)ClinicalTrials.gov · fetched Nov 12, 2026
- ExebacaseMRSA Bloodstream InfectionClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Direct Lysis of Staph Aureus Resistant Pathogen Trial of ExebacasePHASE3 · TERMINATED · started Dec 20, 2019ClinicalTrials.gov NCT04160468 · fetched Nov 12, 2026
- Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus BacteremiaPHASE2 · COMPLETED · started May 23, 2017ClinicalTrials.gov NCT03163446 · fetched Nov 12, 2026
- A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy SubjectsPHASE1 · COMPLETED · started May 1, 2015ClinicalTrials.gov NCT02439359 · fetched Nov 12, 2026
- Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA BacteremiaNO_LONGER_AVAILABLEClinicalTrials.gov NCT04597242 · fetched Nov 12, 2026